Enliven Therapeutics, Inc. (ELVN)
37.00
+0.89
(+2.46%)
USD |
NASDAQ |
Jun 10, 16:00
38.29
+1.29
(+3.49%)
After-Hours: 20:00
Enliven Therapeutics Enterprise Value : 1.801B for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 1.801B |
| June 09, 2026 | 1.747B |
| June 08, 2026 | 1.596B |
| June 05, 2026 | 1.661B |
| June 04, 2026 | 1.709B |
| June 03, 2026 | 1.742B |
| June 02, 2026 | 1.711B |
| June 01, 2026 | 1.832B |
| May 29, 2026 | 1.957B |
| May 28, 2026 | 2.023B |
| May 27, 2026 | 2.070B |
| May 26, 2026 | 2.138B |
| May 22, 2026 | 2.078B |
| May 21, 2026 | 2.121B |
| May 20, 2026 | 2.097B |
| May 19, 2026 | 1.994B |
| May 18, 2026 | 1.962B |
| May 15, 2026 | 2.066B |
| May 14, 2026 | 2.172B |
| May 13, 2026 | 2.201B |
| May 12, 2026 | 2.124B |
| May 11, 2026 | 1.959B |
| May 08, 2026 | 2.030B |
| May 07, 2026 | 2.002B |
| May 06, 2026 | 2.057B |
| Date | Value |
|---|---|
| May 05, 2026 | 2.080B |
| May 04, 2026 | 2.082B |
| May 01, 2026 | 2.088B |
| April 30, 2026 | 2.059B |
| April 29, 2026 | 2.130B |
| April 28, 2026 | 2.166B |
| April 27, 2026 | 2.282B |
| April 24, 2026 | 2.243B |
| April 23, 2026 | 2.221B |
| April 22, 2026 | 2.254B |
| April 21, 2026 | 2.342B |
| April 20, 2026 | 2.374B |
| April 17, 2026 | 2.478B |
| April 16, 2026 | 2.309B |
| April 15, 2026 | 2.224B |
| April 14, 2026 | 2.279B |
| April 13, 2026 | 2.217B |
| April 10, 2026 | 2.308B |
| April 09, 2026 | 2.324B |
| April 08, 2026 | 2.162B |
| April 07, 2026 | 2.176B |
| April 06, 2026 | 1.919B |
| April 02, 2026 | 1.912B |
| April 01, 2026 | 1.849B |
| March 31, 2026 | 1.935B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 10.45M |
| CNBX Pharmaceuticals, Inc. | 1.322M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | -156.09M |
| Fulcrum Therapeutics, Inc. | -93.65M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.63M |
| Total Expenses (Quarterly) | 23.63M |
| EPS Diluted (Quarterly) | -0.3762 |
| Earnings Yield | -4.50% |
| Normalized Earnings Yield | -4.497 |